Even in remission, chronic inflammatory demyelinating polyneuropathy (CIDP) fatigue can be draining. Learn how to use the spoon theory, pacing strategies, and ergonomic tools to manage your "energy ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

IVIg and other treatments for chronic inflammatory demyelinating polyneuropathy (CIDP) slow or stop your immune system’s attack on the protective coating (myelin sheath) around your nerves. But ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for ...

Argenx SE gained U.S. FDA approval of subcutaneously given Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

Living with chronic inflammatory demyelinating polyneuropathy (CIDP) means managing more than physical symptoms. Learn how to handle ‘relapse anxiety’ and differentiate between normal nerve sensations ...

Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis (MG) and initial results from Period 1 of a mid-stage study of the ...

Argenx SE (NASDAQ:ARGX) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of ...